Benefit-Risk assessmentMeSH concept

https://ansm.sante.fr/informations-de-securite/ocaliva-acide-obeticholique-recommandation-dabrogation-de-lautorisation-de-mise-sur-le-marche-conditionnelle-dans-lunion-europeenne-en-raison-dun-benefice-clinique-non-confirme
2024
false
false
false
France
French
risk assessment
Benefit-Risk assessment
drug information
obeticholic acid
obeticholic acid
obeticholic acid
Primary Biliary Cholangitis

---
https://ansm.sante.fr/actualites/prevention-de-la-bronchiolite-du-nourrisson-les-premieres-donnees-de-pharmacovigilance-confirment-le-profil-de-securite-du-nirsevimab-beyfortus
2024
false
false
false
France
French
bronchiolitis, viral
infant, newborn
infant
pharmacovigilance
respiratory syncytial virus infections
nirsevimab
nirsevimab
risks and benefits
Benefit-Risk assessment
hospitalization
investigative report
drug information
technical report
nirsevimab

---
https://www.inesss.qc.ca/covid-19/traitements-specifiques-a-la-covid-19/les-fondements-ethiques-de-levaluation-de-lequilibre-benefices-risques-dun-traitement-prometteur-en-contexte-de-pandemie.html
2021
Canada
coronavirus infections
pneumonia, viral
drug information
Benefit-Risk assessment
pandemics
risk assessment
ethical review
Ethics
COVID-19

---
https://www.anses.fr/fr/system/files/VECTEURS2020SA0057.pdf
2020
France
coronavirus infections
pneumonia, viral
public health guidelines
Dengue
inlets
risk assessment
wrestling
engaged in wrestling
risk-taking
albumin/globulin ratio
Control
Benefit-Risk assessment
Dengue fevers
relative risk
dengue
bays
Practice
containment of biohazards
dengue
risk
pandemics
COVID-19

---
Position Statement of the Francophone Diabetes Society (SFD): Evaluation of the risk-benefit ratio of SGLT2 inhibitors
https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/mmm_isglt2_vf.pdf
2019
false
false
false
false
France
journal article
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
cardiovascular diseases
diabetic nephropathies
algorithms
guideline
risk assessment
Sodium-Glucose Transporter 2 Inhibitors
Benefit-Risk assessment
diabetes mellitus, type 2

---
https://www.anses.fr/fr/content/avis-et-rapport-de-lanses-du-19-novembre-2014-r%C3%A9vis%C3%A9-le-9-janvier-2015-relatifs-%C3%A0-l
2015
false
false
false
false
France
French
scientific and technical information
albumin/globulin ratio
Benefit-Risk assessment
research report
report
relative risk
risk assessment
relative
nutrition assessment
sweetening agents
inlets
risk
bays

---